Prifemilast (HPP737) vs Roflumilast (Zoryve)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: PDE4 · full Psoriasis pipeline
Prifemilast (HPP737)
Developed by Newsoara Biopharma under a licence from vTv Therapeutics
NCT07712731 · Phase 3 · completed
The trial randomized 607 participants to HPP737 or active treatment with apremilast and used triple masking of participants, care providers, and investigators. Its primary endpoints were clinical psoriasis measures.
Reported efficacy
To evaluate proportion of subjects at Week 16 achieving at least a 75% reduction(improvement) from baseline in PASI (Psoriasis Area and Severity Index) score (PASI 75); (From enrollment to end of treatment at 16 weeks); To evaluate proportion of subjects at Week 16 achieving sPGA (Static Physician's Global Assessment) rating of "clear (score 0) or almost clear (score 1)" (From enrollment to end of treatment at 16 weeks): Co-primary endpoints at week 16, prifemilast 20 mg once daily vs apremilast 30 mg twice daily: PASI 75 64.6% vs 35.3% and sPGA 0/1 55.6% vs 31.3% (both P<0.0001) (2026-10-09). (met)
Result source: NCT07712731
Roflumilast (Zoryve)
Marketed by Arcutis Biotherapeutics and partners
NCT06648772 · Phase 3 · completed
The study randomly assigned 190 participants to roflumilast cream or vehicle cream and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was a clinical psoriasis severity measure, but whether that endpoint was met cannot be determined because results are not available.
Next expected readout: July 2027 · NCT07725822 (registry estimate)
Reported efficacy
Number of Participants Achieving Success on the Investigator Global Assessment (IGA) Scale (Week 8): Number of Participants Achieving Success on the Investigator Global Assessment (IGA) Scale (Week 8): Roflumilast Cream 0.3% 99/264 (37.5%) vs Vehicle Cream 9/131 (6.9%) (met)
Result source: NCT04211389
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Prifemilast (HPP737) | Roflumilast (Zoryve) |
|---|---|---|
| PASI 75 | —Not posted · NCT07712731 | 41.6% vs 7.6%+34 vs placeboNCT042113639 other results
|
| PASI 90 | —Not posted · NCT07712731 | 22.4% vs 2.3%+20.1 vs placeboNCT042113639 other results
|
| PASI 100 | —Not posted · NCT07712731 | —Not posted · NCT06648772 |
| sPGA 0/1 | —Not posted · NCT07712731 | —Not posted · NCT06648772 |
| DLQI, change | —Not posted · NCT07712731 | -2.6 vs -1.4−1.2 vs placeboNCT036382587 other results
|
PASI 75
- Prifemilast (HPP737)
- —Not posted · NCT07712731
- Roflumilast (Zoryve)
- 41.6% vs 7.6%+34 vs placeboNCT04211363
9 other results
- 39% vs 5.3% NCT04211389
- 34.1% vs 16% NCT03638258
- 31.1% vs 16% NCT03638258
- 31.3% vs 13.2% NCT03638258
- 23% vs 13.2% NCT03638258
- 24.1% vs 9.6% NCT03638258
- 22.2% vs 9.6% NCT03638258
- 13.3% vs 10.5% NCT03638258
- 7.6% vs 10.5% NCT03638258
PASI 90
- Prifemilast (HPP737)
- —Not posted · NCT07712731
- Roflumilast (Zoryve)
- 22.4% vs 2.3%+20.1 vs placeboNCT04211363
9 other results
- 15.5% vs 2% NCT04211389
- 20.6% vs 7.8% NCT03638258
- 13.7% vs 7.8% NCT03638258
- 16.9% vs 6% NCT03638258
- 7.4% vs 6% NCT03638258
- 14.3% vs 3.2% NCT03638258
- 2.3% vs 3.2% NCT03638258
- 6% vs 2.3% NCT03638258
- 1.3% vs 2.3% NCT03638258
PASI 100
- Prifemilast (HPP737)
- —Not posted · NCT07712731
- Roflumilast (Zoryve)
- —Not posted · NCT06648772
sPGA 0/1
- Prifemilast (HPP737)
- —Not posted · NCT07712731
- Roflumilast (Zoryve)
- —Not posted · NCT06648772
DLQI, change
- Prifemilast (HPP737)
- —Not posted · NCT07712731
- Roflumilast (Zoryve)
- -2.6 vs -1.4−1.2 vs placeboNCT03638258
7 other results
- -4.2 vs -1.4 NCT03638258
- -2.6 vs -1.6 NCT03638258
- -3.5 vs -1.6 NCT03638258
- -2.6 vs -1.8 NCT03638258
- -3.1 vs -1.8 NCT03638258
- -2.2 vs -1.9 NCT03638258
- -2.3 vs -1.9 NCT03638258
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Prifemilast (HPP737): 0 of 4 rows · Roflumilast (Zoryve): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Roflumilast (Zoryve) |
|---|---|
| Dropout rate | 10.8%0.3% creama NCT04211363 · Phase 3 show 10 more results9%0.3% cream NCT04211389 · Phase 3 0%0.3% daily NCT04746911 · Phase 2 · registry result, not featured evidence 0%0.3% cream NCT04655313 · Phase 2 · registry result, not featured evidence 28.7%Cohort 1: Study 201 Participants NCT03764475 · Phase 2 · registry result, not featured evidence 21.6%Cohort 2: Non-study 201 Participan NCT03764475 · Phase 2 · registry result, not featured evidence 8%0.15% NCT03638258 · Phase 2 · registry result, not featured evidence —0.3% NCT03638258 · Phase 2 · registry result, not featured evidence 0%0.5% NCT03392168 · Phase 1/2 · registry result, not featured evidence —0.15% NCT03392168 · Phase 1/2 · registry result, not featured evidence —0.5% NCT03392168 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | 1.7%0.3% creama NCT04211363 · Phase 3 show 10 more results0.3%0.3% cream NCT04211389 · Phase 3 —0.3% daily NCT04746911 · Phase 2 · registry result, not featured evidence —0.3% cream NCT04655313 · Phase 2 · registry result, not featured evidence 4.8%Cohort 1: Study 201 Participants NCT03764475 · Phase 2 · registry result, not featured evidence 2%Cohort 2: Non-study 201 Participan NCT03764475 · Phase 2 · registry result, not featured evidence 0%0.15% NCT03638258 · Phase 2 · registry result, not featured evidence —0.3% NCT03638258 · Phase 2 · registry result, not featured evidence —0.5% NCT03392168 · Phase 1/2 · registry result, not featured evidence —0.15% NCT03392168 · Phase 1/2 · registry result, not featured evidence —0.5% NCT03392168 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | 0.7%0.3% creama NCT04211363 · Phase 3 show 10 more results0%0.3% cream NCT04211389 · Phase 3 0%0.3% daily NCT04746911 · Phase 2 · registry result, not featured evidence 0%0.3% cream NCT04655313 · Phase 2 · registry result, not featured evidence 3.5%Cohort 1: Study 201 Participants NCT03764475 · Phase 2 · registry result, not featured evidence 2%Cohort 2: Non-study 201 Participan NCT03764475 · Phase 2 · registry result, not featured evidence 0.9%0.15% NCT03638258 · Phase 2 · registry result, not featured evidence 0.9%0.3% NCT03638258 · Phase 2 · registry result, not featured evidence 0%0.5% NCT03392168 · Phase 1/2 · registry result, not featured evidence 0%0.15% NCT03392168 · Phase 1/2 · registry result, not featured evidence 0%0.5% NCT03392168 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | show 8 more results0.3% cream application site pain 5% back pain 5% candida infection 5% NCT04655313 · Phase 2 · registry result, not featured evidence upper respiratory tract infection 6.5% NCT03764475 · Phase 2 · registry result, not featured evidence upper respiratory tract infection 6.9% NCT03764475 · Phase 2 · registry result, not featured evidence 0.15% upper respiratory tract infection 6.4% (placebo 0%) NCT03638258 · Phase 2 · registry result, not featured evidence 0.3% upper respiratory tract infection 7.3% (placebo 0%) NCT03638258 · Phase 2 · registry result, not featured evidence 0.5% candiduria 12.5% (placebo 0%) application site erythema 0% (placebo 12.9%) application site pain 0% (placebo 16.1%) NCT03392168 · Phase 1/2 · registry result, not featured evidence 0.15% nasopharyngitis 7.1% (placebo 0%) application site erythema 3.6% (placebo 12.9%) application site pain 3.6% (placebo 16.1%) NCT03392168 · Phase 1/2 · registry result, not featured evidence 0.5% application site erythema 13.3% (placebo 12.9%) application site pain 6.7% (placebo 16.1%) nasopharyngitis 6.7% (placebo 0%) NCT03392168 · Phase 1/2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Roflumilast (Zoryve)
show 1 more result
show 1 more result
show 9 more results
show 9 more results
show 1 more result
show 2 more results
show 2 more results
show 1 more result
show 15 more results
show 1 more result
+ 10 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Prifemilast (HPP737)'s landscape · Roflumilast (Zoryve)'s landscape